Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OCS
stocks logo

OCS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
136.87K
+4462.33%
-0.393
-41.41%
100.00K
-64.91%
-0.497
-27.9%
100.00K
-61.69%
-0.481
-1.76%
Estimates Revision
The market is revising Downward the revenue expectations for Oculis Holding AG (OCS) for FY2025, with the revenue forecasts being adjusted by -3.02% over the past three months. During the same period, the stock price has changed by 14.40%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.31%
In Past 3 Month
Stock Price
Go Up
up Image
+14.40%
In Past 3 Month
Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.700
sliders
Low
29.00
Averages
39.50
High
51.00
Current: 19.700
sliders
Low
29.00
Averages
39.50
High
51.00
BofA
Buy
maintain
$30 -> $29
2025-11-13
Reason
BofA
Price Target
$30 -> $29
2025-11-13
maintain
Buy
Reason
BofA lowered the firm's price target on Oculis to $29 from $30 and keeps a Buy rating on the shares after the company reported Q3 results. The firm, which now incorporates the October equity financing in its model, exits Q3 reiterating its view that Oculis's assets are "underappreciated."
H.C. Wainwright
Yi Chen
Buy
maintain
$36 -> $42
2025-11-11
Reason
H.C. Wainwright
Yi Chen
Price Target
$36 -> $42
2025-11-11
maintain
Buy
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on Oculis to $42 from $36 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's PIONEER registrational program targets an untapped market opportunity of over $7B.
Needham
NULL
to
Buy
initiated
$36
2025-08-27
Reason
Needham
Price Target
$36
2025-08-27
initiated
NULL
to
Buy
Reason
Needham initiated coverage of Oculis with a Buy rating and $36 price target. Lead-asset OCS-01 aims to be the first non-invasive therapy for diabetic macular edema, while OCS-02 offers a biologic mechanism of action for dry-eye disease via eye drop, notes the analyst, who calls Oculis "an under-the-radar story nearing a data-rich period in early-2026."
H.C. Wainwright
Buy
maintain
$32 -> $33
2025-08-22
Reason
H.C. Wainwright
Price Target
$32 -> $33
2025-08-22
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Oculis to $33 from $32 and keeps a Buy rating on the shares following the Q2 report.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$29 → $32
2025-04-17
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$29 → $32
2025-04-17
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$28
2025-04-17
Reason
Chardan Capital
Daniil Gataulin
Price Target
$28
2025-04-17
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Oculis Holding AG (OCS.O) is -9.36, compared to its 5-year average forward P/E of -5.38. For a more detailed relative valuation and DCF analysis to assess Oculis Holding AG 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.38
Current PE
-9.36
Overvalued PE
-1.95
Undervalued PE
-8.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.65
Undervalued EV/EBITDA
-9.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
550.09
Current PS
0.00
Overvalued PS
1054.32
Undervalued PS
45.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OCS News & Events

Events Timeline

(ET)
2025-11-10
16:34:37
Oculis Announces Q3 Earnings Per Share of 32 Cents, Below Consensus Estimate of 41 Cents
select
2025-08-21 (ET)
2025-08-21
16:16:40
Oculis Announces Q2 Earnings Per Share of 49 Cents, Exceeding Consensus Estimate of 43 Cents
select
2024-10-21 (ET)
2024-10-21
13:07:14
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-04NASDAQ.COM
Oculis Holding AG (OCS) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Oculis Holding AG has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Oculis has risen by 7.2% over the past three months, reflecting analysts' growing confidence in the company's future earnings potential.

  • Correlation with Stock Movement: There is a strong correlation between earnings estimate revisions and near-term stock price movements, making the Zacks rating system a valuable tool for investors.

  • Top 20% Ranking: The upgrade places Oculis in the top 20% of Zacks-covered stocks, suggesting it has superior earnings estimate revisions and potential for market-beating returns.

[object Object]
Preview
4.0
12-03Benzinga
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing Buy and Outperform ratings along with price targets.

  • Traws Pharma, Inc.: HC Wainwright & Co. analyst Brandon Folkes initiated coverage with a Buy rating and a price target of $8, while shares closed at $2.16.

  • Compass Therapeutics, Inc.: Canaccord Genuity analyst John Newman also initiated coverage with a Buy rating and a price target of $10, with shares closing at $5.22.

  • Linde plc and Others: CICC analyst Shanshan Shen rated Linde plc as Outperform with a price target of $510, and HC Wainwright initiated coverage on Pelthos Therapeutics and LifeSci Capital on Oculis Holding, both with positive ratings and significant price targets.

[object Object]
Preview
3.0
11-18NASDAQ.COM
Earnings Report Ahead of Market Opening for November 18, 2025: HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL

  • Earnings Reports Overview: Several companies, including Home Depot, PDD Holdings, and Medtronic, are set to report earnings on November 18, 2025, with varying forecasts and trends in earnings growth compared to previous quarters.

  • Home Depot (HD): Expected to report earnings per share (EPS) of $3.81, a slight increase from last year, but has faced negative surprises in the last two quarters.

  • PDD Holdings (PDD) and Baidu (BIDU): PDD anticipates a decrease in EPS to $1.99, while Baidu expects a significant drop to $0.91, both indicating challenges compared to the same quarter last year.

  • Positive Trends in Other Companies: Companies like Elbit Systems and Amer Sports are projected to show strong growth, with EPS increases of 24.43% and 78.57%, respectively, indicating better performance relative to their industry peers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oculis Holding AG (OCS) stock price today?

The current price of OCS is 19.7 USD — it has increased 3.74 % in the last trading day.

arrow icon

What is Oculis Holding AG (OCS)'s business?

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

arrow icon

What is the price predicton of OCS Stock?

Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oculis Holding AG (OCS)'s revenue for the last quarter?

Oculis Holding AG revenue for the last quarter amounts to -20.30M USD, increased 11.94 % YoY.

arrow icon

What is Oculis Holding AG (OCS)'s earnings per share (EPS) for the last quarter?

Oculis Holding AG. EPS for the last quarter amounts to -13324000.00 USD, increased 25.88 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oculis Holding AG (OCS)'s fundamentals?

The market is revising Downward the revenue expectations for Oculis Holding AG (OCS) for FY2025, with the revenue forecasts being adjusted by -3.02% over the past three months. During the same period, the stock price has changed by 14.40%.
arrow icon

How many employees does Oculis Holding AG (OCS). have?

Oculis Holding AG (OCS) has 49 emplpoyees as of December 05 2025.

arrow icon

What is Oculis Holding AG (OCS) market cap?

Today OCS has the market capitalization of 1.10B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free